Replies to post #53445 on $ Ea$y Money Picks $

[ProfitScout]

$CURR is looking good for 2023. The upcoming Q4 financial report is projected to deliver continued revenue growth and improvements based on the successful marketing of the company's wellness and anti-aging product lines.
https://finance.yahoo.com/news/cure-pharmaceutical-reports-third-quarter-110000414.html

From the Q3 results:


*Gross margins for the third quarter improved by 123 basis points to 80.0% in 2022 compared to the same period in 2021 with expectations of continuing high margin sales with our new marketing initiatives.

*SG&A expenses (excluding non-cash charges) for the third quarter decreased by $0.1 million in 2022 compared to 2021.

*Cost reductions and operating leverage helped narrow operating loss (excluding non-cash charges) by $0.6 million in 2022 versus 2021 despite enhanced marketing investment.